HealthMore in Health→
One-Shot Gene Editing Therapy Cuts LDL Cholesterol in Early Trial
Key Takeaways
- A Phase 1b study tested VERVE-102 in 35 adults with inherited high cholesterol or early coronary artery disease.
- At the highest dose, LDL cholesterol fell by up to 62% after a single infusion.
- The therapy works by switching off the PCSK9 pathway in the liver, aiming for a durable one-time effect.
DE
DT Editorial Team··via medicalxpress.com